All News
Dr. Quotes (11.8.2024)
Dr. Jack Cush reviews the news and journal reports from this past week from RheumNow.com.
Read Article
ANA+ consult (10.18.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
I Can't Treat Ugly (9.20.2024)
Dr. Jack Cush reviews the news, journal articles and a new FDA approval for EGPA, this week on the Podcast.
Read Article
BSR Guidelines for Systemic Sclerosis Management
The British Society for Rheumatology (BSR) has updated its 2015 guidelines for the management of patients with sytemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion.
Read Article
Systemic Sclerosis Insights (9.13.2024)
Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com.
Read Article
Risk factors and crystal composition of in calcinosis. In SSc - calcinosis is assc with vasculopathy, dz duration #ACR24 #ACRReview https://t.co/LJvrdVG1jg
TheDaoIndex KDAO2011 ( View Tweet)
171 SSc pts w/ hand Xrays and US found 20% w/ Joint involvement. Active Synovitis & tenosynovitis predicted by CRP>10mg/L (p = 0.013), fibrotic tenosynovitis on US (p = 0.005), anti-RNA polymerase III antibodies (p = 0.043) https://t.co/OIornA9sAA https://t.co/yXyX5k2yqD
Dr. John Cush RheumNow ( View Tweet)
Scleroderma registry enrolled SSc pts w/o ILD. Incident ILD occurred in 199/969 (21%) pts over median 2.4yrs. Late onset SSc-ILD (>7yr from Raynauds) occurs 32% less. These pts were more White, w/ arthritis & RNA-polymerase III Abs, but have similar ILD Progression (vs… https://t.co/zdL4OPEPhi https://t.co/wl9XmsCHIE
Dr. John Cush RheumNow ( View Tweet)
211 SSc patients, men and younger women, have lower BMD than the population (Osteopenia in 52% & 16.5% osteoporosis; P=0.001). Low BMD in women assoc w/ Finger ulcers, diffuse involvement, older age, & being post-menopausal https://t.co/qyvEJoIbKH https://t.co/zj2Fn1oU5n
Dr. John Cush RheumNow ( View Tweet)
EUSTAR study, 257 PSS pts. w/ 12+ mos F/U, skin Dz was 70% stable, 22% regressive, 7% progressive. Regressive skin change pts had significantly lower probability of FVC decline ≥10% & all-cause mortality (p=0.035) vs progressive patients https://t.co/3L9iVTPwKv https://t.co/NMuD8VW7Pu
Dr. John Cush RheumNow ( View Tweet)
Study of AutoAbs in 141 pts w/ systemic sclerosis overlap syndrome (SSc OS). Most common Abs: Ro-52, centromere (ACA) & anti-Scl-70. Scl-70 was assoc w/ ILD & SSc renal crisis (SRC); while ACA is protective factor of ILD. SRC & pulm HTN assoc w/ incr mortality… https://t.co/sqQhIlZjdB https://t.co/noyaFbd3Z8
Dr. John Cush RheumNow ( View Tweet)
ANA+ consult? 2 Yr study of 207 asymptomatic ANA-pos, found only 11% progressed to systemic autoimmune rheum Dz (89% did not). Progressors developed SLE (48%), Sjögren (22%), scleroderma (13%), RA (4%); Arthritis (RR 1.74) more likly in progressors https://t.co/j54Vnsl50V https://t.co/jaPbigaqgS
Dr. John Cush RheumNow ( View Tweet)
ANA+ consult? 2 Yr study of 207 asymptomatic ANA-pos, found only 11% progressed to systemic autoimmune rheum Dz (89% did not). Progressors developed SLE (48%), Sjögren (22%), scleroderma (13%), RA (4%); Arthritis (RR 1.74) more likly in progressors https://t.co/53bmkQ0qj0 https://t.co/8VUxqxnuGl
Dr. John Cush RheumNow ( View Tweet)
GI Abnormalities in Scleroderma
A prospective Scleroderma Cohort Study found that gastrointestinal tract (GIT) involvement was common and negatively impacted quality of life, physical function, and employment, but had no effect on mortality.
https://t.co/6jQvKz7nmm https://t.co/1IGPe6obyS
Dr. John Cush RheumNow ( View Tweet)
Cancer risk increased following, but not before, a systemic sclerosis diagnosis. From a dataset of 10.1 million individuals, 1588 Dx w/ SSc & 206 developed cancer. Most common mucocutaneous (4.5%), lung (2%) breast (2%). Cancer risk higher after the Dx of SSc (HR ~1.4)… https://t.co/9GNMOU28TQ https://t.co/czLEsXymIv
Dr. John Cush RheumNow ( View Tweet)
BSR Guidelines for Systemic Sclerosis Management
The BSR has updated its 2015 guidelines for the management of patients with SSc based on published evidence, systematic literature review and expert opinion.
https://t.co/HdQrK4TKGI https://t.co/O6FeaelWZV
Dr. John Cush RheumNow ( View Tweet)
Increasing Incidence of Morphea
A large EMR cohort study of over 10,000 patients with morphea (localized scleroderma) sheds light on the increasing prevalence of morphea.
https://t.co/ISqv4y0Pkp https://t.co/KM3gbt2iWd
Dr. John Cush RheumNow ( View Tweet)
Study of 115 systemic sclerosis (SSc) pts followed 4 yrs. modified Rodnan skin score @ 4 yrs correlated w/ baseline mRSS & finger-to-palm distance (length from the distal tip of the fourth finger to the distal palmar crease) https://t.co/TwMy5Mh68r https://t.co/4qhhBS9yOH
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/yIBlyNZacB https://t.co/dempwjX5XO
Dr. John Cush RheumNow ( View Tweet)
Systematic literature review IVIG in systemic sclerosis included 12 studies, 266 pts. A favorable effect was seen for skin thickening, MSK pain, GI Sxs, Steroid use, QOL. But less effect for pulmonary Dz, PFTs (stabilized?). Studies were not of high-quality… https://t.co/c3Xix9K2XK https://t.co/L3LKwegmkf
Dr. John Cush RheumNow ( View Tweet)
